We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Variation Increases Hypertension Risk

By Biotechdaily staff writers
Posted on 22 May 2002
Researchers have identified three abnormalities in a single gene that are linked to essential hypertension, the most common class of high blood pressure.

This finding, reported in the March 19, 2002, issue of the Proceedings of the National Academy of Sciences, is the result of an 18-year collaboration between researchers at the University of Virginia (Charlottesville, USA) and Georgetown University (Washington DC, USA).

Essential hypertension affects 25% of adults and constitutes a major risk factor for stroke, heart attack, heart failure, and kidney failure. More...
About 50% percent of essential hypertension is thought to be hereditary, but determining the genetic cause has been difficult, as the level of blood pressure is the result of the interplay between heredity and environment.

Genetic variations, or polymorphisms, either by themselves or through interaction with variations of other genes, are associated with hypertension. The presence of polymorphisms can be determined by a simple genetic test developed by the researchers. This test assesses an individual's risk of developing high blood pressure based on the detection of inherited gene variations that encode for a protein called G protein coupled receptor kinase type 4 (GRK4). GRK4 variations are associated with an inability to normally eliminate sodium from the body. Sodium in the diet has long been regarded as contributing to high blood pressure.

"Patients with even a single GRK4 variation have a significant lifetime risk for developing hypertension,” said Dr. Pedro A. Jose, the senior author of the paper. "We have now identified the genetic abnormalities that cause this error and so we have a better idea of the impact of these gene variations in the development of hypertension in three distinct racial groups.”

This discovery has led to a high-quality test based on a fluorescent molecular beacon assay that should be suitable for screening a large number of patients and will help doctors diagnose genetic forms of hypertension, according to Robin A. Felder, Ph.D., the lead author on the paper. "The genetic information disclosed by the test will allow physicians to provide guidance to patients with a family history of hypertension.”




Related Links:
University of Virginia
Georgetown University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.